Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Pediatric and Endocrinology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Eur J Med Genet. 2022 Sep;65(9):104536. doi: 10.1016/j.ejmg.2022.104536. Epub 2022 Jun 8.
Phenylalanine hydroxylase enzyme defects result in a hereditary metabolic disorder called phenylketonuria. Sapropterin (tetrahydrobiopterin) is one of the treatment strategies for this disorder. Even though a correlation between genotype and BH4 responsiveness was established by earlier studies, a subset of mutations often presented inconsistent responses and/or phenotypes. Different genetic background is one of the potential reasons for this fact. In this study, the genotype of a total of 34 PAH deficient patients from Khorasan-Razavi providence in the north-east of Iran was obtained. Among this patients, 21 individuals took the 24 h and 48 h BH4 loading test and if the result was positive, their Phenylalanine tolerance was assessed. It is the first study of its type in patients from Iran to evaluate genotype role in predicting the most probable responsive individuals. The known pathogenic variant p.R169P and the novel variant p. Leu72_Asp75delinsTyr were first classified as responsive.Seven genotypes were reported as responsive for the first time. All patients carrying at least one pathogenic variant, which was previously reported as BH4 responsive, respond to BH4. Three patients with p.L48S, p.R261Q and p.A309V pathogenic variants were exceptions. There was no certain statistical correlation between genotype and response. Genotype and phenotype were significantly correlated and majority of patients with mild phenotype carried at least one non-null pathogenic variant. In Khorasan-Razavi province of Iran, patients with at least one non-null mutation are most probable to demonstrate mild phenotype and respond to BH4 phenotype.
苯丙氨酸羟化酶酶缺陷导致一种称为苯丙酮尿症的遗传性代谢紊乱。萨普瑞特林(四氢生物蝶呤)是治疗这种疾病的策略之一。尽管早期的研究已经确定了基因型与 BH4 反应之间的相关性,但一部分突变通常表现出不一致的反应和/或表型。不同的遗传背景是造成这种情况的潜在原因之一。在这项研究中,获得了来自伊朗东北部的霍拉桑-拉扎维省的 34 名 PAH 缺乏患者的基因型。在这些患者中,21 人接受了 24 小时和 48 小时 BH4 负荷试验,如果结果为阳性,则评估他们的苯丙氨酸耐量。这是伊朗患者评估基因型在预测最可能有反应的个体中的作用的首例此类研究。已知的致病性变异 p.R169P 和新的变异 p.Leu72_Asp75delinsTyr 首次被归类为有反应。首次报道了 7 种基因型为有反应。所有携带至少一种以前报道为 BH4 有反应的致病性变异的患者均对 BH4 有反应。携带 p.L48S、p.R261Q 和 p.A309V 致病性变异的 3 名患者是例外。基因型与反应之间没有确定的统计学相关性。基因型与表型显著相关,大多数表型较轻的患者携带至少一种非无效致病性变异。在伊朗的霍拉桑-拉扎维省,至少携带一种非无效突变的患者最有可能表现出轻度表型并对 BH4 表型有反应。